Your clinical trial enrollment is lagging behind — here’s how to speed it back up

Many biotech board members and executives have experienced it – that sinking feeling when clinical trial enrollment curves shift right again, when ​“minor delays” compound into major financing crises, and when optimistic projections collide with harsh operational realities. As RA Capital’s new SABER module bluntly states: ​“Our whole ecosystem is built on a giant lie that we can forecast trial timelines and budgets with any accuracy.”

Despite our best efforts, clinical trial execution remains stubbornly unpredictable, with delays and budget overruns threatening even the most promising programs. But biotech leaders can now access a proven framework for tackling this universal challenge through RA Capital’s Gateway platform and RA Capital’s website.